NRC IRAP

Isotechnika Pharma receives funding from NRC-IRAP

Thursday, June 27, 2013

Biopharmaceutical Isotechnika Pharma has received additional funding from the Canadian National Research Council Industrial Research Assistance Program (“NRC-IRAP”) for its Non-Immunosuppressive Cyclophilin Antagonist Molecules (“NICAMs”) program. NRC-IRAP helped network the NICAM program with global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including evaluation of anti-hepatitis C virus (“HCV”) activity.

[Read More]